Enhancement of mucosal immunity and CTL avidity against HIV-1

增强粘膜免疫和 CTL 对 HIV-1 的亲和力

• 批准号: nhmrc : 525431
• 负责人: A/Pr Charani Ranasinghe
• 金额: $ 36.88万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/enhancement-mucosal-immunity-hiv-1/95730
• 关键词: Enhancement; mucosal; immunity; CTL; avidity

Production of strong antiviral immunity at the local mucosa (genito-rectal track) is essential for protection against HIV-AIDS. We believe that expression of small hormone-like molecules known as Th2 cytokines IL-4-IL-13 negatively influence the generation of protective immunity against HIV. Thus we aim to counteract these effects by co-expressing proteins known as chemokines together with vaccine antigens to improve the quality of mucosal vaccine immunity.

局部粘膜（生殖直肠轨道）产生强大的抗病毒免疫力对于预防艾滋病毒/艾滋病至关重要。我们认为，称为 Th2 细胞因子 IL-4-IL-13 的类激素小分子的表达会对 HIV 保护性免疫的产生产生负面影响。因此，我们的目标是通过共表达称为趋化因子的蛋白质与疫苗抗原来抵消这些影响，以提高粘膜疫苗免疫的质量。